Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of KYN-5356 in healthy adults aged 18 to 55 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Dysfunction
• Schizophrenia

Drugs mentioned

• KYN-5356 (KYN-5356)

Snippet

Sponsor: Kynexis B.V. | Conditions: Cognitive Dysfunction, Schizophrenia | Phase 1 | Status: COMPLETED